alkermes plc - ALKS
ALKS
Close Chg Chg %
29.24 -0.89 -3.04%
Closed Market
28.35
-0.89 (3.04%)
Volume: 1.14M
Last Updated:
Nov 14, 2024, 4:00 PM EDT
Company Overview: alkermes plc - ALKS
ALKS Key Data
| Open $29.11 | Day Range 28.29 - 29.30 |
| 52 Week Range 22.07 - 32.88 | Market Cap $4.73B |
| Shares Outstanding 161.80M | Public Float 158.72M |
| Beta 0.47 | Rev. Per Employee N/A |
| P/E Ratio 14.89 | EPS $2.00 |
| Yield 0.00% | Dividend $1.67 |
| EX-DIVIDEND DATE Nov 16, 2023 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.81M |
ALKS Performance
| 1 Week | 1.32% | ||
| 1 Month | 3.43% | ||
| 3 Months | 7.30% | ||
| 1 Year | 20.63% | ||
| 5 Years | 41.50% |
ALKS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
13
Full Ratings ➔
About alkermes plc - ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS At a Glance
Alkermes Plc
Connaught House
Dublin, Dublin 4
| Phone | 353-1-772-8000 | Revenue | 1.66B | |
| Industry | Pharmaceuticals: Major | Net Income | 355.76M | |
| Sector | Health Technology | 2023 Sales Growth | 49.614% | |
| Fiscal Year-end | 12 / 2024 | Employees | 2,100 | |
| View SEC Filings |
ALKS Valuation
| P/E Current | 14.894 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 13.235 |
| Price to Sales Ratio | 2.831 |
| Price to Book Ratio | 3.851 |
| Price to Cash Flow Ratio | 11.731 |
| Enterprise Value to EBITDA | 8.807 |
| Enterprise Value to Sales | 2.589 |
| Total Debt to Enterprise Value | 0.086 |
ALKS Efficiency
| Revenue/Employee | 792,097.619 |
| Income Per Employee | 169,408.095 |
| Receivables Turnover | 4.992 |
| Total Asset Turnover | 0.811 |
ALKS Liquidity
| Current Ratio | 2.856 |
| Quick Ratio | 2.497 |
| Cash Ratio | 1.487 |
ALKS Profitability
| Gross Margin | 82.065 |
| Operating Margin | 24.896 |
| Pretax Margin | 25.341 |
| Net Margin | 21.387 |
| Return on Assets | 25.323 |
| Return on Equity | 46.22 |
| Return on Total Capital | 32.965 |
| Return on Invested Capital | 34.726 |
ALKS Capital Structure
| Total Debt to Total Equity | 30.946 |
| Total Debt to Total Capital | 23.633 |
| Total Debt to Total Assets | 17.423 |
| Long-Term Debt to Equity | 30.219 |
| Long-Term Debt to Total Capital | 23.077 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Alkermes Plc - ALKS
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.04B | 1.17B | 1.11B | 1.66B | |
Sales Growth
| -11.29% | +13.00% | -5.28% | +49.61% | |
Cost of Goods Sold (COGS) incl D&A
| 232.87M | 247.74M | 266.47M | 298.33M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 81.85M | 78.65M | 77.86M | 74.93M | |
Depreciation
| 42.40M | 40.50M | 41.50M | 39.24M | |
Amortization of Intangibles
| 39.45M | 38.15M | 36.36M | 35.69M | |
COGS Growth
| -0.80% | +6.38% | +7.56% | +11.95% | |
Gross Income
| 805.89M | 926.02M | 845.32M | 1.37B | |
Gross Income Growth
| -13.92% | +14.91% | -8.71% | +61.49% | |
Gross Profit Margin
| +77.58% | +78.89% | +76.03% | +82.07% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 918.32M | 955.30M | 987.59M | 950.96M | |
Research & Development
| 379.49M | 394.33M | 381.84M | 261.21M | |
Other SG&A
| 538.83M | 560.98M | 605.75M | 689.75M | |
SGA Growth
| -9.23% | +4.03% | +3.38% | -3.71% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (3.94M) | 450.00K | 21.75M | |
EBIT after Unusual Expense
| (108.48M) | (29.74M) | (164.01M) | 414.12M | |
Non Operating Income/Expense
| 20.60M | 1.65M | 9.75M | 30.43M | |
Non-Operating Interest Income
| 6.96M | 2.41M | 7.63M | 30.85M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 8.66M | 11.22M | 13.04M | 23.03M | |
Interest Expense Growth
| -36.34% | +29.56% | +16.23% | +76.63% | |
Gross Interest Expense
| 8.66M | 11.22M | 13.04M | 23.03M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (96.54M) | (39.31M) | (167.30M) | 421.52M | |
Pretax Income Growth
| +51.01% | +59.28% | -325.64% | +351.95% | |
Pretax Margin
| -9.29% | -3.35% | -15.05% | +25.34% | |
Income Tax
| 14.32M | 8.86M | (9.04M) | (97.64M) | |
Income Tax - Current - Domestic
| 4.34M | 3.78M | 23.76M | (259.00K) | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 9.98M | 5.08M | (32.80M) | 9.69M | |
Income Tax - Deferred - Foreign
| - | - | - | (107.06M) | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (110.86M) | (48.17M) | (158.27M) | 519.16M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (110.86M) | (48.17M) | (158.27M) | 519.16M | |
Net Income Growth
| +43.62% | +56.55% | -228.57% | +428.03% | |
Net Margin Growth
| -10.67% | -4.10% | -14.24% | +31.21% | |
Extraordinaries & Discontinued Operations
| - | - | - | (163.40M) | - |
Discontinued Operations
| - | - | - | (163.40M) | - |
Net Income After Extraordinaries
| (110.86M) | (48.17M) | (158.27M) | 355.76M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (110.86M) | (48.17M) | (158.27M) | 355.76M | |
EPS (Basic)
| -0.6981 | -0.2993 | -0.9678 | 2.1402 | |
EPS (Basic) Growth
| +44.24% | +57.13% | -223.35% | +321.14% | |
Basic Shares Outstanding
| 158.80M | 160.94M | 163.54M | 166.22M | |
EPS (Diluted)
| -0.6981 | -0.2993 | -0.9678 | 2.096 | |
EPS (Diluted) Growth
| +44.24% | +57.13% | -223.35% | +316.57% | |
Diluted Shares Outstanding
| 158.80M | 160.94M | 163.54M | 169.73M | |
EBITDA
| (30.57M) | 49.37M | (64.40M) | 489.05M | |
EBITDA Growth
| -719.51% | +261.47% | -230.46% | +859.36% | |
EBITDA Margin
| -2.94% | +4.21% | -5.79% | +29.40% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 33.583 | |
| Number of Ratings | 13 | Current Quarters Estimate | 0.746 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 2.624 | |
| Last Quarter’s Earnings | 0.72 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.44 | Next Fiscal Year Estimate | 1.775 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 5 | 10 | 11 |
| Mean Estimate | 0.75 | 0.39 | 2.62 | 1.78 |
| High Estimates | 0.96 | 0.60 | 2.80 | 2.17 |
| Low Estimate | 0.37 | 0.30 | 2.25 | 0.81 |
| Coefficient of Variance | 22.01 | 31.48 | 6.05 | 22.56 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 7 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 4 | 5 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Alkermes Plc - ALKS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Alkermes Plc - ALKS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 11, 2024 | Emily Peterson Alva Director | 22,663 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.91 per share | 541,872.33 |
| Jun 11, 2024 | Emily Peterson Alva Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 11, 2024 | Christopher I. Wright Director | 9,777 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.91 per share | 233,768.07 |
| Jun 11, 2024 | Christopher I. Wright Director | 3,301 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 11, 2024 | Christopher I. Wright Director | 10,570 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 11, 2024 | Emily Peterson Alva Director | 23,593 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 5, 2024 | David Antonio Daglio Director | 17,492 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 5, 2024 | Nancy L. Snyderman Director | 27,948 | Other acquisition or disposition | 0.00 |
| Jun 5, 2024 | Nancy L. Snyderman Director | 16,524 | Other acquisition or disposition | 0.00 |
| Jun 5, 2024 | Nancy L. Snyderman Director | 14,484 | Other acquisition or disposition | 0.00 |
| Jun 5, 2024 | Nancy L. Snyderman Director | 17,850 | Other acquisition or disposition | 0.00 |
| Jun 5, 2024 | Nancy L. Snyderman Director | 11,739 | Other acquisition or disposition | 0.00 |
| Jun 5, 2024 | Nancy L. Snyderman Director | 15,990 | Other acquisition or disposition | 0.00 |
| Jun 5, 2024 | David Antonio Daglio Director | 8,013 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 5, 2024 | Nancy L. Snyderman Director | 8,013 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 5, 2024 | Nancy Sue Lurker Director | 17,492 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 5, 2024 | Shane M. Cooke Director | 56,227 | Other acquisition or disposition | 0.00 |
| Jun 5, 2024 | Nancy L. Snyderman Director | 17,492 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 5, 2024 | Brian Patrick McKeon Director | 8,013 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 5, 2024 | Nancy Sue Lurker Director | 8,013 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |